Androgen deprivation therapy (ADT) continues to be central to the treatment of advanced prostate cancer (PCa). This article summarises data presented at the Global Congress on Prostate Cancer (PROSCA) 2023, held in Málaga, Spain, focusing on practical approaches to the use of ADT in complex clinical scenarios.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Thank you!
Please share some more information on the rating you have given